Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency (Review)


This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1

http://www.thecochranelibrary.com

Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEADER</td>
<td>1</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>PLAIN LANGUAGE SUMMARY</td>
<td>2</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>2</td>
</tr>
<tr>
<td>OBJECTIVES</td>
<td>3</td>
</tr>
<tr>
<td>METHODS</td>
<td>3</td>
</tr>
<tr>
<td>RESULTS</td>
<td>5</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>8</td>
</tr>
<tr>
<td>AUTHORS' CONCLUSIONS</td>
<td>9</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>9</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>10</td>
</tr>
<tr>
<td>CHARACTERISTICS OF STUDIES</td>
<td>14</td>
</tr>
<tr>
<td>DATA AND ANALYSES</td>
<td>20</td>
</tr>
<tr>
<td>APPENDICES</td>
<td>20</td>
</tr>
<tr>
<td>WHAT'S NEW</td>
<td>23</td>
</tr>
<tr>
<td>HISTORY</td>
<td>23</td>
</tr>
<tr>
<td>CONTRIBUTIONS OF AUTHORS</td>
<td>23</td>
</tr>
<tr>
<td>DECLARATIONS OF INTEREST</td>
<td>24</td>
</tr>
<tr>
<td>SOURCES OF SUPPORT</td>
<td>24</td>
</tr>
<tr>
<td>INDEX TERMS</td>
<td>24</td>
</tr>
</tbody>
</table>

Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]

Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency

Josep Vidal-Alaball¹, Christopher Butler², Rebecca Cannings-John³, Andrew Goringe³, Kerry Hood², Andrew McCaddon⁴, Ian McDowell⁵, Alexandra Papaioannou⁶

¹National Public Health Service for Wales, Swansea, UK. ²Department of Primary Care and Public Health, School of Medicine, Cardiff University, Cardiff, UK. ³Department of Haematology, Cardiff and Vale NHS Trust, Cardiff, UK. ⁴Department of General Practice, Wales College of Medicine, Cardiff University, Wrexham, UK. ⁵Department of Medical Biochemistry and Immunology, Cardiff University, Cardiff, UK. ⁶Department of Medicine, McMaster University, Hamilton, Canada

Contact address: Josep Vidal-Alaball, National Public Health Service for Wales, 36 Orchard Street, Swansea, Wales, SA1 5AQ, UK. Josep.Vidal-Alaball@nphs.wales.nhs.uk

Editorial group: Cochrane Metabolic and Endocrine Disorders Group.

Publication status and date: Edited (no change to conclusions), published in Issue 1, 2009.

Review content assessed as up-to-date: 30 December 2004.


Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Vitamin B12 deficiency is common and rises with age. Most people with vitamin B12 deficiency are treated in primary care with intramuscular vitamin B12 which is a considerable source of work for health care professionals. Several case control and case series studies have reported equal efficacy of oral administration of vitamin B12 but it is rarely prescribed in this form, other than in Sweden and Canada. Doctors may not be prescribing oral formulations because they are unaware of this option or have concerns regarding effectiveness.

Objectives

To assess the effectiveness of oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency.

Search methods

Searches were undertaken of The Cochrane Library, MEDLINE, EMBASE and Lilacs. The bibliographies of all relevant papers identified using this strategy were searched. In addition we contacted authors of relevant identified studies and Vitamin B12 research and pharmaceutical companies to enquire about other published or unpublished studies and ongoing trials.

Selection criteria

Randomised controlled trials (RCTs) examining the use of oral or intramuscular vitamin B12 to treat vitamin B12 deficiency.

Data collection and analysis

All abstracts or titles identified by the electronic searches were independently scrutinised by two reviewers. When a difference between reviewers arose, we obtained and reviewed a hard copy of the papers and made decisions by consensus. We obtained a copy of all pre-selected papers and two researchers independently extracted the data from these studies using piloted data extraction forms. The whole group checked whether inclusion and exclusion criteria were met, and disagreement was decided by consensus. The methodological quality of the included studies was independently assessed by two researchers and disagreements were brought back to the whole group and resolved by consensus.
Main results

Two RCT’s comparing oral with intramuscular administration of vitamin B12 met our inclusion criteria. The trials recruited a total of 108 participants and followed up 93 of these from 90 days to four months. High oral doses of B12 (1000 mcg and 2000 mcg) were as effective as intramuscular administration in achieving haematological and neurological responses.

Authors’ conclusions

The evidence derived from these limited studies suggests that 2000 mcg doses of oral vitamin B12 daily and 1000 mcg doses initially daily and thereafter weekly and then monthly may be as effective as intramuscular administration in obtaining short term haematological and neurological responses in vitamin B12 deficient patients.

PLAIN LANGUAGE SUMMARY

Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency

Vitamin B12 deficiency can cause anaemia and neurological complications. Vitamin B12 is rarely prescribed in the oral form in most countries. Two randomised controlled studies were included in this review. The trials recruited a total of 108 participants and followed up 93 of these from 90 days to four months. The evidence derived from these limited studies suggests that high oral doses of B12 (1000 mcg and 2000 mcg) could be as effective as intramuscular administration in achieving haematological and neurological responses.

BACKGROUND

Description of the condition

Vitamins are a group of substances required for effective human metabolism. Under normal circumstances it is essential that they are present in a person’s diet because, with few exceptions, the human body is unable to manufacture them. Vitamins often work together with enzymes, co-factors, and other substances. Vitamin B12 (cobalamin) is necessary for the development of red blood cells, growth, and nervous system maintenance. The only dietary sources of vitamin B12 are animal products, such as eggs, fish and meats. Daily requirements are age-related; the recommended dietary amounts for adults and infants are 1.5 mcg and 0.4 mcg respectively (FAO/WHO 1988, DH 1991).

Vitamin B12 is absorbed in the terminal ileum. This absorption is almost entirely dependent upon intrinsic factor (IF), a glycoprotein secreted by parietal cells situated in the mucosa of the stomach. IF binds to Vitamin B12 and the complex is transported across the cell membrane bound to another glycoprotein called transcobalamin. The most common cause of vitamin B12 deficiency is autoimmune pernicious anaemia, a condition that carries an increased risk of gastric cancer. In pernicious anaemia absorption is impaired due to IF deficiency arising from autoimmune destruction of parietal cells. Other common causes of vitamin B12 deficiency include gastrectomy, ileal resection, pancreatic insufficiency and malabsorption syndromes including Crohn’s disease and coeliac disease. Other less common causes include use of drugs such as biguanides (metformin), antacids (proton pump inhibitors and H2 receptors antagonists), aminoglycoside antibiotics, colchicines, and rarely malabsorption due to gastrointestinal bacterial overgrowth and infestation. Pure nutritional deficiency is rare and usually occurs only in strict vegans (EVM 2002).

The true prevalence of vitamin B12 deficiency in the general population is still uncertain but there is evidence that it is common, especially amongst the elderly. The incidence of vitamin B12 deficiency increases with age, probably due to the fact that elderly people are more likely to suffer from food-cobalamin malabsorption. This malabsorption is caused primarily by gastric atrophy but also by chronic carriage of Helicobacter pylori, long term ingestion of metformin and proton pump inhibitors and increased chances of having gastric surgery (Andres 2004). The prevalence of vitamin B12 deficiency in the elderly varies substantially in different studies, largely because of inconsistent diagnostic criteria for vitamin B12 deficiency. Prevalence figures between 1.5% and 15% have been reported (Clarke 2004; Figlin 2003; Pennypacker 1992; Rajan 2002; van Walraven 1999). As well as varying with age, prevalence also varies with gender and ethnic group; elderly men are more likely to have low vitamin B12 levels than elderly women and the prevalence of vitamin B12 deficiency is higher in Europe than in the USA (Lindenbaum 1994; Pennypacker 1992). Vitamin B12 deficiency causes symptoms very similar to folate de-
ficiency: megaloblastic anaemia, chronic tiredness, loss of appetite and mood disturbance. If left untreated, serious neurological and neuropsychiatric complications occur. Vitamin B12 deficiency has also been linked with an increased risk of myocardial infarction and stroke; however this link has not been proved to be causal and it is sustained on the relation between high homocysteine levels and cardiovascular events (Nygard 1997, Carmel 2003). The diagnosis of vitamin B12 deficiency is based mainly on blood measurements of serum vitamin B12, complemented with second line tests including total homocysteine and methylmalonic acid levels which are metabolic indicators of vitamin B12 deficiency. Studies have indicated that some patients, mainly elderly, can present with neuropsychiatric symptoms in the absence of haematological abnormalities (Lindeman 1988).

**Description of the intervention**

Vitamin B12 (cobalamin) was first isolated in its cyano- form in 1948 (Rickes 1948; Smith 1948), and is now widely used for the treatment of vitamin B12 deficiency. Vitamin B12 replacement has been traditionally administered intramuscularly. However several case control and case series studies have since suggested equal efficacy and safety of the oral route (Chalmers 1958; Ross 1954; Spies 1949). The mechanism for this oral route is most probably that free vitamin B12 can be absorbed both passively (without binding to IF) as well as actively (following binding to IF) in the terminal ileum. Passive diffusion accounts for 1.2% of total absorption with a bioavailability unaffected in patients with pernicious anaemia or gastro-duodenal surgical resection (Berlin 1968; Berlin 1978). High doses of oral vitamin B12 (e.g. 1,000 micrograms daily) may be able to produce adequate absorption of vitamin B12 even in the presence of IF deficiency and therefore be an alternative to the intramuscular route in many patients. Despite availability in most countries and a very safe track record, vitamin B12 is rarely prescribed in the oral form. In Sweden, however, in the year 2000, oral vitamin B12 accounted for 73% of the total vitamin B12 prescribed (Norberg 2001; Nilsson 2005). Oral vitamin B12 is also widely used in Canada. Possible reasons for doctors not prescribing oral formulations include unawareness of this option or concerns regarding unpredictable absorption (Lederle 1991; Lederle 1998). In the UK, oral vitamin B12 is not currently available on NHS prescription in high dose formulations. Most vitamin B12 deficient individuals in the UK and other countries are treated with intramuscular vitamin B12. Intramuscular vitamin B12 can be administered in two different forms: cyanocobalamin and hydroxocobalamin. In some countries hydroxocobalamin has completely replaced cyanocobalamin as first choice for vitamin B12 therapy because it is retained in the body longer and can be administered at intervals of up to three months (BNF 2004). Intramuscular injections are a “considerable source of work” for health care professionals, mainly general practitioners and community nurses (Middleton 1985), and can cause significant pain in thin patients (Elia 1998). While serious adverse reactions are rare, injections can be dangerous in anticoagulated patients. There is little difference in the cost of oral versus intramuscular therapy when the medication alone is considered. However, intramuscular administration often involves a special trip to a health facility or a home visit by a health professional to administer the injection (Lederle 1991). Oral treatment could therefore save considerable Health Service resources.

Archie Cochrane, working in South Wales, was one of the first to identify that substantial financial savings could be made from more evidence-based prescribing of vitamin B12. His focus was on excessive prescription of vitamin B12 (Cochrane 1971). More recently, a Canadian study (van Walraven 2001) has estimated that converting patients aged over 65 years on B12 replacement from the intramuscular to oral form could save between $2.9 and $17.6 million (2.5 and 15.3 million Euro) over five years in Ontario alone.

**Why it is important to do this review**

There have been several case control and non-randomised studies assessing the effectiveness of oral vitamin B12 over the last five decades (e.g. Andres 2001; Andres 2003a; Berlin 1968; McIntyre 1960; Spies 1949). We identified a narrative review (Lane 2002) but did not identify any systematic review comparing oral vitamin B12 with intramuscular administration.

**OBJECTIVES**

To assess the effects of oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency.

**METHODS**

Criteria for considering studies for this review

**Types of studies**

Randomised controlled trials examining the use of oral versus intramuscular vitamin B12 to treat vitamin B12 deficiency. No minimum trial duration or post intervention follow-up restriction.

Exclusions:

- studies examining the role of vitamin B12 in the prevention of cardio-vascular diseases, because the dose of vitamin B12 used in those studies may be different from the dose used to treat
vitamin B12 deficiency and the majority of patients included in these studies are not vitamin B12 deficient; • studies of patients with primary folate deficiency, because the concomitant use of folate might confound the metabolic outcome measures; • studies of patients with end-stage renal disease or on haemodialysis, because renal disease might confound the metabolic outcome measures.

Types of participants
Study participants with low serum vitamin B12 levels, meeting criteria for vitamin B12 replacement therapy. We used a cut-off point of 180 pmol/L (or 240 pg/mL) as threshold serum level for vitamin B12 deficiency. Although there has been some controversy regarding the cut-off point to define vitamin B12 deficiency, values between 120 and 180 pmol/L have been consistently used and 180 pmol/L is a value that ensures a wider inclusion of studies.

Types of interventions
Oral vitamin B12 versus intramuscular vitamin B12.

Types of outcome measures
Primary outcomes
• serum vitamin B12 levels;
• clinical signs and symptoms of vitamin B12 deficiency (e.g., depression, tiredness, paralysis, dementia).

Secondary outcomes
• haemoglobin and mean corpuscular volume (MCV);
• total homocysteine and serum methylmalonic acid levels;
• costs;
• adverse effects of oral and intramuscular vitamin B12 treatment;
• acceptability to patients;
• quality of life (ideally measured with a validated instrument).

Search methods for identification of studies
Electronic searches
We did not have any language restrictions. We searched the following databases:
• The Cochrane Library (Issue 1, 2005), including the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Reviews of Effectiveness (DARE);
• MEDLINE (up to December 2004);
• EMBASE (up to December 2004);
• Lilacs - www.bireme.br (up to December 2004).

To identify ongoing trials we searched:
• The National Research Register (UK) (http://www.update-software.com/national);
• Current Controlled Trials (http://www.controlled-trials.com);
• National Institutes of Health (USA) (http://clinicalstudies.info.nih.gov).

Our search strategy was based on the strategy described in the Cochrane Reviewers’ Handbook (Optimal Search Strategy for RCTs, Appendix 5c). The search strategy was used for searches of MEDLINE Ovid Web and adapted for other electronic databases. For the detailed search strategy see Appendix 1.

It was agreed that if during our search we identified any additional key words of relevance, we would adapt our strategy accordingly and re-run the search.

Searching other resources
The bibliographies of all relevant papers identified by this strategy were searched for additional studies.
We contacted (by e-mail or letter) the authors of relevant studies, experts in the field and Vitamin B12 manufacturers to enquire about additional published or unpublished studies, ongoing trials and to obtain additional references.

Data collection and analysis
Selection of studies
All abstracts or titles identified by the electronic searches were independently scrutinised by two researchers (JVA examined all the abstracts and divided the abstracts between CCB, RCJ and KH to provide a second review). When uncertainty arose, or when there were differences between these reviewers, we obtained and reviewed the hard copies of papers and made decisions by consensus.

The whole group checked whether inclusion and exclusion criteria were met and disagreement was resolved by consensus.

Data extraction and management
We obtained a copy of all selected papers. JVA extracted data from all the papers and another researcher (either AMC or RCJ) also extracted data from each paper using piloted data extraction forms.
Assessment of risk of bias in included studies
The methodological quality of the included studies were independently assessed by two researchers (CCB and RCJ) and disagreements brought back to the whole group for discussion.

We used the scheme described in the Cochrane Collaboration Handbook for assessing methodological quality. This scheme uses the criteria specified by Schulz and by Jadad (Jadad 1996; Schulz 1995) and involves assessing studies for:

- publication bias
- selection bias - a) was the randomisation procedure adequate? b) was the allocation concealment adequate?
- performance bias - a) were the patients and people administering the treatment blind to the intervention?
- attrition bias - a) were withdrawals and dropouts completely described? b) was analysis by intention-to-treat?
- detection bias - were outcome assessors adequately blinded to the intervention patients received?

Based on these criteria a 3-point rating scale was used, with the following grading:
A - all quality criteria met: low risk of bias (plausible bias is unlikely to alter the results seriously)
B - one or more of the quality criteria only partly met: moderate risk of bias (plausible bias raises some doubt about the results)
C - one or more criteria not met: high risk of bias (plausible bias seriously weakens confidence in the results)

Data synthesis
We planned to perform meta-analysis if studies were sufficiently similar in terms of inclusion criteria, settings, treatment, follow up assessment and quality. We aimed to evaluate equivalence between the oral and intramuscular routes of vitamin B12 administration. We planned to report serum concentrations of vitamin B12, homocysteine and methylmalonic acid and sources of clinical outcome of both routes of administration, oral and parenteral, giving mean differences and confidence intervals. For other outcome measures, relative risk with 95% confidence intervals or effect sizes will be reported.

We intended to assess sources of heterogeneity in order to determine whether variation observed in the results could be explained by chance alone. We intended to use the chi-squared test and the I-squared test to examine evident heterogeneity between the trials (Higgins 2002). If significant heterogeneity was evident (P < 0.1), we could have attempted to determine reasons through subgroup and sensitivity analyses.

If in the future adequate data become available we will use this method of analysis.

Subgroup analysis and investigation of heterogeneity
We planned subgroups for the following:

- Newly diagnosed patients
- Patients already established on intramuscular treatment
- People over 65 years of age
- Patients who had had stomach or small bowel resection
- Vegetarians
- Patients taking anti-ulcer medication over long periods
- Patients with dementia
- Patients with acquired immunodeficiency syndrome

Sensitivity analysis
When relevant, we planned to repeat the analysis:
- excluding studies published in abstract form only;
- taking account of study quality, as specified above;
- excluding any unusually long term or large studies;
- excluding studies using the following filters: source of funding (industry versus other), country.

We planned to test the robustness of the results by repeating the analysis using different measures of effect size (risk difference, odds ratio etc.) and different statistical models (fixed and random effects models).

RESULTS

Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.

Data extraction
Two groups of researchers independently extracted data from the two randomised studies that met the inclusion criteria using piloted data extraction forms. The characteristics are described in the table Characteristics of included studies. We did not extract data from non-randomised studies or studies that clearly did not meet the inclusion criteria. The whole group checked all the relevant studies in relation to inclusion and exclusion criteria.

Language
Most of the publications were written in English (88%), but we found seven papers that we felt warranted closer scrutiny written in other languages: Italian (Aguzzi 1985; Migliorini 1979), French (Brassinne 1974; De La Fourniere 1997; Kaltenbach 2003), Danish (Bastrup-Madsen 1973) and Czech (Bezdickova 1997).

JVA and MF independently assessed the Italian studies. JVA and DP assessed the three French studies. BN and AMH independently assessed the Danish study. JVA and CCB assessed the English
abstracts of the Czech study and this study was excluded on the basis of the abstract alone.

**Results of the search**

Our initial search included studies published before 2003. After the protocol was published, we decided to include the studies published during 2003 and 2004. After manually removing all duplicates, we pre-selected 797 abstracts identified by searches. We selected 41 abstracts for which the full paper was obtained and two studies met the inclusion criteria.

**Handsearching**

Searching the bibliographies of the selected articles and other relevant studies identified another 15 studies for which we obtained the full text.

A total of 56 studies were thus selected for review of the full paper.

**Additional search strategies**

Clinical experts (Dr Norberg, Dr Burr, Dr Dempsey and Dr Ledetle) authors of relevant identified studies (Dr Andres, Dr Nyholm, Dr Bolaman and Dr Allen) and Vitamin B12 manufacturers (Goldshield Pharmaceuticals, Link Pharmaceuticals and Celltech Group) were contacted to enquire about other published or unpublished studies, ongoing trials and to obtain additional references. No additional studies were identified in this way.

**Interrater agreement**

Each stage of selection of studies was followed by discussions with the group. The process resulted in agreement in the pre-selection stage, the quality of the assessment, and in the data extraction phase. We did not use kappa statistic (Cohen 1960) because during the pre-selection phase we obtained hard copies of any study independently identified by researchers. When assessing the methodological quality of the included studies kappa statistic was not calculated as just two studies met the inclusion criteria.

**Included studies**

Two randomised control trials (Bolaman 2003; Kuzminska 1998) fulfilled our inclusion criteria. Characteristics of these studies are shown in Characteristics of included studies

**Study types**

Two studies compared oral administration of vitamin B12 versus intramuscular administration of vitamin B12. The two studies were randomised controlled trials.

**Participants**

The trials recruited a total of 108 participants and followed up 93 of these from 90 days to four months. 52 participants were female (56%) and 41 were male (44%). Participants in both studies had low serum vitamin B12 levels and both were set in outpatient hospital clinics. The first study was carried out in USA by Kuzminska and colleagues (Kuzminska 1998) and the second in Turkey by Bolaman and colleagues (Bolaman 2003).

Kuzminska and colleagues recruited 38 patients with a mean age of 72 years for the oral group and 71 years for the intramuscular group. 28 of these patients had conditions that may be associated with malabsorption from the gut (including seven with pernicious anaemia and three with ileal resection), although patients with inflammatory bowel disease and coeliac disease appear not to have been included.

Bolaman and colleagues recruited 70 patients with a mean age of 60 years for the oral group and 64 years for the intramuscular group. 35 of these patients had conditions affecting the ileum that may be associated with malabsorption from the gut. Again, however, patients with inflammatory bowel disease and coeliac disease appear not to have been included.

Patient inclusion and exclusion criteria in individual studies are outlined in Characteristics of included studies.

**Interventions**

The two studies compared oral administration of vitamin B12 versus intramuscular administration of vitamin B12. The duration of the intervention was the same as the duration of the follow up. The dose of oral vitamin B12 used by Kuzminska and colleagues was 2,000 mcg (Kuzminska 1998); Bolaman and colleagues used 1,000 mcg (Bolaman 2003). The dose of intramuscular vitamin B12 was 1,000 mcg in both studies and it was administered by nurses.

**Outcome measures**

Several primary outcomes measures were reported in the studies:

- Serum vitamin B12
- Haemoglobin
- Mean Corpuscular Volume (MCV)
- White Blood Cells (WBC)
- Platelet count
- Methylmalonic Acid
- Homocysteine
- Folate
- Serum creatinine
- Fasting serum gastrin
- Parietal and intrinsic factor antibodies
- Mini-Mental State Examination
- Neurologic assessment
Only one of the studies (Bolaman 2003) in addition reported about tolerability of medication (assessed by a haematologist and patient interviews), and costs, assessed by the authors using cost of the study drug and the injections.

Excluded studies
Fifty-four studies were excluded. Reasons for exclusion of studies are given in Excluded studies. The most common reason for exclusion was a non-randomised trial design (57%) or the study did not meet intervention criteria (35%).

Risk of bias in included studies
Further details of the methodological quality of the included studies can be found in Appendix 2.

Allocation
One of the studies (Kuzminski 1998) did not describe attempts to conceal the assignment of participants.

Blinding
The two studies (Bolaman 2003; Kuzminski 1998) were not blinded, as patients knew whether they were taking oral or intramuscular medication since no placebo was used.

Incomplete outcome data
In the study by Kuzminski and colleagues (Kuzminski 1998), 38 participants were randomised but five participants were excluded from the final analysis because they were judged to have primary folate deficiency rather than Vitamin B12 deficiency. The final analysis included 18 participants in the oral group and 15 randomised to receive intramuscular treatment. Three participants randomised to receive intramuscular vitamin B12 had a total of seven samples excluded from the analysis because of an error in taking the specimen. However the samples were judged valid for assay of serum metabolites. The authors did not analyse according to intention to treat.

In the study by Bolaman and colleagues (Bolaman 2003), 70 participants were enrolled in the study but 10 were excluded because failure to appear to follow up. The final analysis included 26 participants in the oral group and 34 randomised to receive intramuscular treatment. The authors did not analyse according to intention to treat.

Other potential sources of bias

Sample size calculation
None of the studies reported a sample size calculation.

Length of follow-up
The length of follow up ranged from 90 days to four months. We consider this as insufficient because of the long biological half-life of body stores of vitamin B12. This is estimated to be more than 30 months (Basu 1996).

Effects of interventions
Two studies compared oral and intramuscular vitamin B12: Kuzminski and colleagues (Kuzminski 1998) reported neurologic and haematologic responses. Four of the eighteen participants randomised to receive oral vitamin B12 and four of the fifteen randomised to receive intramuscular vitamin B12 had a neurological response with a marked improvement or clearing of paresthesias, ataxia, or memory loss. Serum vitamin B12 levels were significantly higher in the oral (643 +/- 328 pg/mL) compared to the intramuscular group (306 +/- 118 pg/mL) at 2 months (P<0.001). The difference was even greater at four months (1,005 +/- 595 vs. 325 +/- 165 pg/mL; P< 0.0005). Serum methylmalonic acid concentrations decreased to < 3 SD above the normal range in all participants except one in the oral and two in the intramuscular group. Mean concentrations of the metabolites were not significantly different between the oral and the intramuscular groups, except at four months, when the value was higher in the intramuscular group (P< 0.05). Elevated serum total homocysteine decreased to 3 SD above the normal range in most participants, but the decrease was over four months in the oral group and during the first month in the intramuscular group. However, in two patients in each group the response was not optimal.

Bolaman and colleagues (Bolaman 2003) reported neurologic and haematologic responses. Both groups receiving oral or intramuscular vitamin B12 reported improvements of cognitive function, sensory neuropathy and vibration sense but the difference between both groups was not statistically significant. Serum vitamin B12 levels increased in those receiving oral and those receiving intramuscular vitamin B12 for 90 days. The authors reported a statistically significant difference between day 0 and day 90 within both groups (P< 0.001) but did not analyse differences between both groups.

Heterogeneity and subgroup analyses
It was not possible to investigate heterogeneity or to do subgroup analysis as the four studies differed markedly in terms of interventions. Sensitivity analyses were not possible.
due to the small number of studies that met the inclusion criteria. We could have included more studies if we had considered participants with normal vitamin B12 levels at study entry but the objective of the review was to look at the use of vitamin B12 for the treatment of vitamin B12 deficiency. Adverse effects, acceptability and quality of life. Only one of the studies mentioned adverse effects and tolerability (Bolaman 2003). In this study, the authors stated that the oral treatment was better tolerated but they did not report on how they assessed tolerability. None of the studies gave an account of the effect of the intervention in the quality of life of participants. Costs. Costs were reported in one of the included trials (Bolaman 2003). In the trial, the cost of the treatment was $80 (66 Euro) per participant in the oral group and $220 (184 Euro) per participant in the intramuscular group (P<0.001). Authors did not report which economic analysis was performed.

**DISCUSSION**

**Summary of main results**

We identified two randomised controlled trials directly relevant to the study question. The follow-up period ranged between 90 days to four months. A total of 108 patients with vitamin B12 deficiency participated in these studies. After consideration of study populations, treatments, outcome measures and follow up, we concluded that meta-analysis was not appropriate. A major consideration was heterogeneity of oral treatment regimes and diverse eligibility for study entry. The authors of the two studies comparing oral with intramuscular administration of vitamin B12 concluded that oral vitamin B12 was as effective as the intramuscular treatment. Kuzminski and colleagues (Kuzminski 1998) concluded that 2000 mcg daily of oral cyanocobalamin was as effective or even superior to 1000 mcg of the same medication administered intramuscularly every month. Bolaman and colleagues (Bolaman 2003) concluded that 1000 mcg of oral or intramuscular vitamin B12 daily for 10 days followed by once weekly for four weeks and once monthly for life was equally effective to treat patients with megaloblastic anaemia. Neither study was blinded. However, the conclusions were based on haematological as well as neurological responses to both treatments and laboratory assessments were likely to have been blinded. A crucial aspect our study addresses is whether or not patients with conditions that might cause malabsorption can be safely treated with oral vitamin B12 in primary care. This was difficult to ascertain because in the trials numbers are small, follow up short and trials did not include patients with common conditions that might interfere with absorption in the terminal ileum such as Crohn's disease, coeliac disease or ulcerative colitis. Three patients with ileal resection and seven with pernicious anaemia were included in one of the studies. Despite these cautions, we did find evidence of a satisfactory short term response to oral vitamin B12 replacement even in patients with some conditions, mainly affecting the upper gastrointestinal tract that may be associated with malabsorption.

**Overall completeness and applicability of evidence**

The studies included older participants with a mean age ranging from 60 to 72. This is consistent with the higher prevalence of Vitamin B12 deficiency amongst the elderly (Rajan 2002; van Walraven 1999). However, the regimen described in the two studies, will be particularly challenging for the elderly with dementia. None of the studies was conducted in Primary Care where most of the patients with vitamin B12 deficiencies are treated; this makes the generalisability of the results more difficult. Another factor affecting generalisability is that the four studies used different treatment regimes and used strict and numerous exclusion criteria. The study conducted by Kuzminski and colleagues (Kuzminski 1998) used injectable cyanocobalamin and not hydroxocobalamin. The bioavailability of the water solution of cyanocobalamin used is much lower than that of more usual injectable preparations such as hydroxocobalamin. For example, Glass and co-workers showed that 69% of a dose of 1000 mcg of cyanocobalamin given as injection was recovered in the urine over 72 hours. The corresponding percentage after an injection of 1000 mcg of hydroxocobalamin was 27% (Glass 1961). The amount of retained B12 would therefore be quite low in the injection group in this particular study. This probably explains why oral B12 appeared to be more effective than this particular injectable preparation. In one of the studies using higher doses of oral vitamin B12 (Bolaman 2003), the authors reported that no adverse events occurred. This is consistent with previous studies (Hathcock 1991). The outcomes were limited and the length of follow up was probably too short to demonstrate effectiveness of the oral treatment, this makes the applicability of the results difficult.

**Potential biases in the review process**

This body of evidence has serious limitations as it includes only two open studies with relatively short follow up periods (90 days and four months) and small number of participants (n = 38 and n = 70) with some attrition. In addition, there are methodological limitations to both studies identified by our search strategy. In one of the studies (Kuzminski 1998) the method of randomisation it is not described. Allocation concealment was adequate in just one study (Bolaman 2003). Intention to treat analysis and blinding was not performed or mentioned in any of the studies. We did not carry out meta-analysis because of heterogeneity of designs, dosages and participants.
Agreements and disagreements with other studies or reviews

We identified many studies assessing the effectiveness of oral vitamin B12, but they were not randomised. The studies, dating from the early 50’s to recently, were mainly before and after studies and all show that patients with vitamin B12 deficiency respond to oral vitamin B12 replacement therapy in clinical and/or laboratory terms (Andres 2001; Andres 2003a; Berlin 1968; Brody 1959; Chalmers 1958; Conley 1952; Conley 1955; Hemsted 1958; Kondo 1998; McIntyre 1960; Reisner 1955; Spies 1949; Unglaud 1955; Ungley 1950; Verhaeverbeke 1997; Waife 1963). However, it is not clear in most of these studies how many included patients suffered from conditions that may cause malabsorption.

AUTHORS’ CONCLUSIONS

Implications for practice

The limited evidence identified in this systematic review shows that high doses of oral vitamin B12 (2000 mcg) daily are as effective as the intramuscular administration (Kuzminska 1998) in obtaining haematological and neurological responses in patients with vitamin B12 deficiency. High doses of oral vitamin B12 (1000 mcg) initially daily and thereafter weekly and then monthly are also as effective as intramuscular vitamin B12 (Bolaman 2003).

The included studies also showed limited evidence for a satisfactory haematological, biochemical and clinical short term response for oral B12 replacement in some patients with conditions associated with malabsorption.

Current clinical practice in UK and in most countries is to prescribe vitamin B12 in the intramuscular form for the treatment of vitamin B12 deficiency. This has been the norm for the last 50 years despite several non-randomised studies in the early 1950’s demonstrating satisfactory responses to oral treatment and the fact that there is considerable experience in Sweden in using oral vitamin B12. In 1998, the study by Kuzminska et al. (Kuzminska 1998) was the first randomised controlled trial to show that in achieving a satisfactory neurological, haematological and biochemical response, daily high doses of oral vitamin B12 were as effective or even more effective than intramuscular vitamin B12 when treating patients with vitamin B12 deficiency.

Generalised oral vitamin B12 treatment might benefit many patients in terms of fewer visits to health carers and reduced discomfort associated with injections. Nursing time would be released for treating other patients. However, adherence and monitoring will remain important considerations, regardless of route of administration.

Implications for research

The above evidence has not been sufficient to change practice in most countries. A further large, pragmatic trial in a primary care setting is needed to determine whether oral vitamin B12 is effective in patients with major common cases of malabsorption and to provide additional evidence regarding cost effectiveness.

In addition, clinicians are often concerned about patient preferences regarding treatment route. General Practitioners commonly report that patients receiving intramuscular vitamin B12 are reluctant to reduce the frequency of their injections or change from intramuscular to oral vitamin B12 replacement, despite having serum vitamin B12 levels several times the normal range. Many patients receive vitamin B12 injections more often than the recommended three month interval (Cochrane 1971; Fraser 1995; van Walraven 1999). Some individuals started on vitamin B12 for ‘tiredness’, but with normal haematological and biochemical parameters, report feeling better on the injections and are reluctant to stop them. This suggests that intramuscular B12 may carry additional psychotropic effects for patients, exceeding those associated with normalisation of serum vitamin B12 serum levels. In a recent qualitative and quantitative study, 73% of patients were willing to try oral vitamin B12 and of those who tried the oral therapy 71% wished to permanently switch. They mentioned travel inconveniences as reasons for preferring the oral route (Kwong 2005).

However, in another non-randomised control trial, researchers attempted to convert patients in primary care from intramuscular to oral vitamin B12 replacement but only half agreed to participate in the study (Nyholm 2003). Possible psychotropic effects are important because they may make General Practitioners and patients reluctant to change to oral therapy, despite evidence that this route is as effective and probably cheaper than the intramuscular route. A deep understanding of patient’s preferences, explaining possible psychotropic effects of intramuscular vitamin B12 therapy, and developing effective ways of reaching shared decisions with patients is probably the way forward.

Further research is therefore needed to avoid perpetuating oral vitamin B12 replacement as one of “medicine’s best kept secrets” (Lederle 1991).

ACKNOWLEDGEMENTS

- Mirella Longo (School of Care Science, University of Glamorgan, Pontypridd) assessed the Italian articles.
- Diana Pasterfield (Department of General Practice, Wales College of Medicine, Wrexham) assessed the French studies.
- Dr Bo Norberg (Department of Internal Medicine, University Hospital of Northern Sweden, Sweden) and Dr Anne-

Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mette Hvas (Department of Clinical Biochemistry, University of Aarhus, Denmark) assessed the Danish study.

- Dr Bolaman, Dr Burr, Dr Nyholm, Dr Dempsey, Dr Lederle, Dr Andres and Dr Allen were contacted to enquire about other published or unpublished studies, ongoing trials and to obtain additional references.

- Members of the Cardiff University Vitamin B12 Group, including Prof Mark Worwood, Dr Michael Burr and Mr Dick Ellis supported the process.

REFERENCES

References to studies included in this review

Bolaman 2003 {published data only}

Kuzminski 1998 {published data only}

References to studies excluded from this review

Adachi 2000 {published data only}

Aguzzi 1985 {published data only}

Altay 1999 {published data only}

Andres 2001 {published data only}

Andres 2003 {published data only}

Andres 2003b {published data only}

References to studies excluded from this review

Anonymous 1997 {published data only}

Bastrup-Madsen 1973 {published data only}

Berlin 1968 {published data only}

Bezdickova 1997 {published data only}

Boddy 1968 {published data only}

Brassinne 1974 {published data only}
Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Migliorini 1979 [published data only]

Naurath 1995 [published data only]

Nyholm 2003 [published data only]

Pathy 1972 [published data only]

Reisner 1955 [published data only]

Rhode 1995 [published data only]

Ross 1954 [published data only]

Saltzman 1993 [published data only]

Seal 2002 [published data only]

Skouby 1970 [published data only]

Slot 1997 [published data only]

Spies 1949 [published data only]

Tin 1978 [published data only]

Tudhope 1967 [published data only]

Uhlbink 1994 [published data only]

Unglaud 1955 [published data only]

Ungley 1950 [published data only]

van Asselt 2001 [published data only]

Verhaverbeke 1997 [published data only]

Waife 1963 [published data only]

Additional references

Altman 1999

Andre 2004

Basiu 1996
Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Berlin 1968

Berlin 1978

BNF 2004

Carmel 2003

Clarke 2004

Cochrane 1971

Cohen 1960

Cobalamin 1988

Cobalamin 1994

DH 1991

Elia 1998

EVM 2002

FAO/WHO 1988

Figlin 2003

Fraser 1995

Glass 1961

Hatfield 1991

Higgins 2002

Jadad 1996

Kwong 2005

Lane 2002

Lederle 1991

Lederle 1998

Lindenbaum 1988

Lindenbaum 1994

Middleton 1985

Nilsson 2005
Norberg 2001

Nygard 1997

Pennypacker 1992

Rajan 2002

Rickes 1948

Ross 1954

Schulz 1995

Smith 1948

Spies 1949

van Walraven 1999

van Walraven 2001

* Indicates the major publication for the study
# Characteristics of Studies

## Characteristics of included studies  
*ordered by study ID*

**Bolaman 2003**

| Methods | Allocation: randomised  
<table>
<thead>
<tr>
<th></th>
<th>Observation period: 90 days</th>
</tr>
</thead>
</table>
| Participants | Patients with megaloblastic anaemia due to cobalamin deficiency  
| | Numbers:
| | 70 patients enrolled, 10 excluded. Outcomes measured for 60 patients.  
| | 26 oral group, 34 intramuscular group.  
| | 14 patients with atrophic gastritis, 7 with chronic antral gastritis, 7 with chronic pangastritis, 6 with alkaline reflux gastritis and 1 with erosive gastritis  
| | Age:  
| | Mean age 60 (+/-15) for the oral group and 64 (+/-10) for the intramuscular group  
| | Inclusion criteria:  
| | - Serum cobalamin level <160pg/mL  
| | - Megaloblastic anaemia  
| | - MCV>94 fl  
| | Exclusion criteria:  
| | - Vomiting and/or diarrhoea  
| | - Alcohol use >40 g/d  
| | - Incapacity to give informed consent  
| | - History of malignancy  
| | - Folate deficiency  
| | - Inability to ingest oral medication  
| | - Use of medication might interfere with folate metabolism  
| | - Pregnant or possibly pregnant  
| | - Breastfeeding  
| Interventions | 1000 mcg cobalamin oral or intramuscular once daily for 10 days. After 10 days, once a week for 4 weeks and after that patients were asked to continue treatment once a month indefinitely  
| Outcomes | Primary Outcomes:  
| | - Serum cobalamin  
| | - Mini-Mental State Examination  
| | - Neurologic assessment  
| | Additional Outcomes:  
| | - Haemoglobin  
| | - MCV  
| | - WBC  
| | - Platelet count  
| | - Tolerability  
| | - Costs  
| | - Side effects not reported  
| Notes | Not blinded  

---

*Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency (Review)*  
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Kuzminski 1998

**Methods**
- Allocation: randomised
- Observation period: 4 months

**Participants**
- Newly diagnosed cobalamin deficient patients
- Numbers: 38 randomised. Outcomes measured for 33 patients
- 17 patients with chronic atrophic gastritis, 7 with pernicious anaemia, 3 with ileal resection, 1 with gastric stapling
- Age: Mean age 72 (+/- 11) for the oral group and 71 (+/- 15) for the intramuscular group
- Inclusion criteria:
  - Serum cobalamin level <160pg/mL
  - Elevation of serum methylmalonic acid, total homocysteine or both metabolites >3 SD’s above the mean in normal controls
- Exclusion criteria:
  - Location outside immediate geographical area
  - Incapacity to give informed consent
  - Refusal to participate
  - Associated life-threatening illness
  - Primary Folate deficiency

**Interventions**
- 1000 mcg intramuscular cyanocobalamin on days 1, 3, 7, 10, 14, 21, 30, 60 and 90
- 2000 mcg oral cyanocobalamin daily for 120 days

**Outcomes**
- Primary Outcomes:
  - Serum cobalamin
  - Neurologic responses
- Additional Outcomes:
  - Methylmalonic Acid
  - Homocysteine
  - Side effects not reported

**Notes**
- Not blinded

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

---

Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency (Review)  
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Characteristics of excluded studies [ordered by study ID]**

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adachi 2000</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Aguzzi 1985</td>
<td>Randomised, placebo-controlled double-blinded study assessing the effectiveness of a product mixture containing cyanocobalamin in the treatment of age-dependent psychic regression. No evidence that patients were vitamin B12 deficient</td>
</tr>
<tr>
<td>Altay 1999</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Andres 2001</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Andres 2003</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Andres 2003a</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Andres 2003b</td>
<td>Same patients as in Andres 2003, letter in a different publication</td>
</tr>
<tr>
<td>Andres(2) 2003</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Bastrup-Madsen 1973</td>
<td>Randomised study but comparing intramuscular hydroxocobalamin and intramuscular cyanocobalamin</td>
</tr>
<tr>
<td>Berlin 1968</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Bezickova 1997</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Boddy 1968</td>
<td>Cross-over study comparing subjects without vitamin B12 deficiency</td>
</tr>
<tr>
<td>Brassinne 1974</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Brody 1959</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Brody 1967</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Chalmers 1958</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Chalmers 1965</td>
<td>Study comparing intramuscular injections of hydroxocobalamin and cyanocobalamin</td>
</tr>
<tr>
<td>Conley 1952</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Study</td>
<td>Designation</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Conley 1955</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>De La Fourniere 1997</td>
<td>Randomised, placebo-controlled double-blinded study assessing use of intramuscular vitamin B12 in dementia</td>
</tr>
<tr>
<td>Ellis 1973</td>
<td>Randomised, cross-over double-blinded study comparing intramuscular hydroxocobalamin and intramuscular placebo in tiredness</td>
</tr>
<tr>
<td>Glass 1966</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Hedstrand 1969</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Hemsted 1958</td>
<td>Study comparing intramuscular injections monthly with oral treatment daily. The study does not state whether patients were randomised</td>
</tr>
<tr>
<td>Hughes 1970</td>
<td>Randomised, placebo-controlled double-blinded study comparing intramuscular hydroxocobalamin with placebo</td>
</tr>
<tr>
<td>Hvas 2003</td>
<td>Randomised, placebo-controlled double-blinded study comparing intramuscular vitamin B12 with placebo</td>
</tr>
<tr>
<td>Kaltenbach 2003</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Killander 1968</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Kondo 1998</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Kwok 1998</td>
<td>Randomised controlled study comparing intramuscular cyanocobalamin with no treatment</td>
</tr>
<tr>
<td>Mader 1988</td>
<td>Randomised, placebo-controlled double-blinded study using an oral multivitamin preparation containing folic acid in headaches. No data available regarding vitamin B12 levels</td>
</tr>
<tr>
<td>Mann 1987</td>
<td>Randomised, placebo-controlled blinded study using a multivitamin/mineral preparation containing folic acid. Most of the patients were had not vitamin B12 deficiency</td>
</tr>
<tr>
<td>Martin 1992</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Mauro 2000</td>
<td>Randomised, placebo-controlled double-blinded study studying efficacy of intramuscular vitamin B12 in the treatment of low back pain</td>
</tr>
<tr>
<td>McIntyre 1960</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Migliorini 1979</td>
<td>Randomised controlled double-blinded study looking at the effect of intramuscular vitamin B12 in pain</td>
</tr>
<tr>
<td>Naurath 1995</td>
<td>Double-blinded placebo controlled study using an intramuscular multivitamin preparation</td>
</tr>
<tr>
<td>Nyholm 2003</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Authors</td>
<td>Study Type</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>Pathy 1972</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Reisner 1955</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Rhode 1995</td>
<td>Study comparing different doses of oral vitamin B12 treatment. No placebo group. No randomisation apparent</td>
</tr>
<tr>
<td>Ross 1954</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Saltzman 1993</td>
<td>Unable to locate study as part of a supplement</td>
</tr>
<tr>
<td>Seal 2002</td>
<td>Randomised controlled study comparing different doses of oral cyanocobalamin with oral placebo</td>
</tr>
<tr>
<td>Skouby 1970</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Slot 1997</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Spies 1949</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Tin 1978</td>
<td>Randomised, placebo-controlled double-blinded study comparing the effect of intramuscular cyanocobalamin and placebo on physical performance</td>
</tr>
<tr>
<td>Tudhope 1967</td>
<td>Randomised study comparing intramuscular hydroxocobalamin and intramuscular cyanocobalamin</td>
</tr>
<tr>
<td>Ubbink 1994</td>
<td>Randomised, placebo-controlled blinded study looking at the effect of vitamin supplementation on hyperhomocysteinemia. Some patients receiving vitamin B12 were not vitamin B12 deficient</td>
</tr>
<tr>
<td>Unglaud 1955</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Ungley 1950</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>van Asselt 2001</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Verhaeverbeke 1997</td>
<td>Non-randomised study</td>
</tr>
<tr>
<td>Waife 1963</td>
<td>Non-randomised study</td>
</tr>
</tbody>
</table>
DATA AND ANALYSES

This review has no analyses.

APPENDICES

Appendix 1. Search strategy

Electronic searches

Unless otherwise stated, search terms were free text terms; exp = exploded MeSH: Medical subject heading (Medline medical index term); the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw = text word; pt = publication type; sh = MeSH: Medical subject heading (Medline medical index term); adj = adjacency.

1. vitamin$ b12.tw.
2. vitamin$ b 12.tw.
3. cobalamin$.tw.
4. hydroxycobalamin$.tw.
5. cyanocobalamin$.tw.
6. betolvex.tw.
7. exp Vitamin B 12/ae, cl, ct, tu [Adverse Effects, Classification, Contraindications, Therapeutic Use]
8. exp Hydroxocobalamin/ae, tu [Adverse Effects, Therapeutic Use]
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp Vitamin B 12 Deficiency/
11. vitamin B12 deficiency$.tw.
12. vitamin B 12 deficiency$.tw.
14. b12 deficiency$.tw.
15. 10 or 11 or 12 or 13 or 14
16. randomized-controlled trial.pt.
17. controlled-clinical trial.pt.
18. randomized-controlled-trials.sh.
19. random allocation.sh.
20. double-blind method.sh.
22. or/16-21
23. animal.sh.
24. human.sh.
25. 23 not 24
26. 22 not 25
27. clinical trial.pt.
28. exp clinical trials/
30. ((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.
31. Placebos.sh.
Appendix 2. Methodological quality of included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Randomisation</th>
<th>Alloc. Conceal.</th>
<th>Blinding</th>
<th>N. Randomised</th>
<th>Withdrawals</th>
<th>Intent to treat</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kuzminski</td>
<td>Unclear</td>
<td>Unclear</td>
<td>No</td>
<td>38</td>
<td>5</td>
<td>No</td>
<td>4 months</td>
</tr>
<tr>
<td>1998</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bolaman</td>
<td>Block randomisation method</td>
<td>Probably adequate</td>
<td>No</td>
<td>70</td>
<td>10</td>
<td>No</td>
<td>90 days</td>
</tr>
<tr>
<td>2003</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Appendix 3. Data extraction sheet

<table>
<thead>
<tr>
<th>Items</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screener’s name</td>
</tr>
<tr>
<td>Study number and name</td>
</tr>
<tr>
<td>Author</td>
</tr>
<tr>
<td>Publication</td>
</tr>
<tr>
<td>Language of Publication</td>
</tr>
<tr>
<td>-------------------------</td>
</tr>
<tr>
<td>Year of publication</td>
</tr>
<tr>
<td>Country</td>
</tr>
<tr>
<td>Type of study (case control, case series, article, RCT ...)</td>
</tr>
<tr>
<td>Treatments</td>
</tr>
<tr>
<td>Inclusion - Exclusion criteria</td>
</tr>
<tr>
<td>Numbers recruited</td>
</tr>
<tr>
<td>Numbers randomised</td>
</tr>
<tr>
<td>Numbers lost to follow up</td>
</tr>
<tr>
<td>Why? (reasons)</td>
</tr>
<tr>
<td>Numbers excluded</td>
</tr>
<tr>
<td>Why? (reasons)</td>
</tr>
<tr>
<td>Withdraws</td>
</tr>
<tr>
<td>Why? (reasons)</td>
</tr>
<tr>
<td>Outcomes measures (biochemical, functional)</td>
</tr>
<tr>
<td>Randomisation. If yes:</td>
</tr>
<tr>
<td>* Length of follow up</td>
</tr>
<tr>
<td>* Follow up points</td>
</tr>
<tr>
<td>* Side effects</td>
</tr>
<tr>
<td>* N. Evaluated in each group</td>
</tr>
<tr>
<td>* N. Responded in each group</td>
</tr>
<tr>
<td>Quality (Cochrane criteria)</td>
</tr>
<tr>
<td>a) low risk of bias (plausible bias is unlikely to alter the results seriously)</td>
</tr>
<tr>
<td>b) moderate risk of bias (plausible bias raises some doubt about the results)</td>
</tr>
</tbody>
</table>
c) high risk of bias (plausible bias seriously weakens confidence in the results)

Blinding. If yes:

* Method of blinding

Intention-to-treat analysis

Additional treatment (co-interventions)

Power calculation (stats)

**WHAT’S NEW**

Last assessed as up-to-date: 30 December 2004.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 November 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
</tbody>
</table>

**HISTORY**

Protocol first published: Issue 1, 2004

Review first published: Issue 3, 2005

**CONTRIBUTIONS OF AUTHORS**

JOSEP VIDAL-ALABALL: Coordination, searching, protocol writing, data extraction, interpretation of data, report writing.

CHRISTOPHER C BUTLER: Formulation of study question, searching, protocol writing, data extraction, piloting form for data extraction, study quality assessment, interpretation of data, report writing.

KERENZA HOOD: Statistical advice on study design, study quality assessment, suitability of data for meta-analysis, interpretation of data and report writing.

REBECCA CANNINGS-JOHN: Data extraction, report writing, meta-analysis.

ANDREW MCCADDON: Advice about appropriate biochemical and clinical endpoint, design and piloting of data extraction form, critical appraisal of findings, report writing.

ALEXANDRA PAPAIOANNOU: Clinical appraisal of findings, report writing, expertise on care of older people with long term medication.


DECLARATIONS OF INTEREST

We have not received any commercial sponsorship for this review.

Dr Andrew McCaddon is a Scientific Consultant for, and shareholder of, COBALZ LIMITED - a private company developing 'glutathionylcobalamin' as an alternative orally available form of vitamin B12.

SOURCES OF SUPPORT

Internal sources

• Department of General Practice, Wales College of Medicine, Cardiff University, UK.
• National Public Health Service for Wales, Wales, UK.

External sources

• No sources of support supplied

INDEX TERMS

Medical Subject Headings (MeSH)

Administration, Oral; Injections, Intramuscular; Randomized Controlled Trials as Topic; Vitamin B 12 [*administration & dosage]; Vitamin B 12 Deficiency [*drug therapy]; Vitamin B Complex [*administration & dosage]

MeSH check words

Aged; Humans